{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T23:12:53Z","timestamp":1768864373935,"version":"3.49.0"},"reference-count":44,"publisher":"Societatea Romana de Morfologie","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rom J Morphol Embryol"],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:p>Aim: This study aimed to assess the clinical and morphological characteristics of patients with visceral melanoma metastases and primary extracutaneous melanomas. Patients, Materials and Methods: We performed a retrospective study on patients with visceral melanoma metastases and primary extracutaneous melanomas, diagnosed in two pathology departments. Results: We identified 50 cases of visceral metastases and eight cases of primary extracutaneous melanomas. A percentage of 56% of the distant metastases involved the brain, 28% were localized in the digestive tract (stomach, small bowel, colon, liver, cystic duct), 16% involved the lung, spleen, adrenal gland, peritoneum, urinary bladder and bone. In 34% of the cases, the metastases were diagnosed prior to the primary melanoma. A percentage of 62.5% of primary extracutaneous melanomas were ocular melanomas, 25% were anal mucosa melanomas and one case (12.5%) involved the penile glans. Statistical analysis showed that distant melanoma metastases were more frequently diagnosed in the seventh decade (p 0.0001), and a higher percentage of patients lived in urban areas (p=0.001). The majority of the primary cutaneous melanomas associated with brain metastases were located on the trunk (p=0.0565). The brain metastases were more frequently diagnosed in males (64%; p=0.0604). Conclusions: The brain is the most frequent organ involved by distant melanoma metastases, followed by the digestive tract. It is important to be aware of the least common metastatic locations such as cystic duct, urinary bladder, adrenal gland, spleen and peritoneum, in order to avoid misdiagnosis.<\/jats:p>","DOI":"10.47162\/rjme.66.3.05","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:41:45Z","timestamp":1768819305000},"page":"479-488","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of the clinical and morphological characteristics of visceral melanoma metastases and primary extracutaneous melanomas"],"prefix":"10.47162","volume":"66","author":[{"name":"Anapatmol Research Center, Victor Babe\u015f University of Medicine and Pharmacy, Timi\u015foara, Romania","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca Roxana","family":"Natar\u00e2\u015f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alis Liliana Carmen","family":"Dema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Anapatmol Research Center, Victor Babe\u015f University of Medicine and Pharmacy, Timi\u015foara, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aura","family":"Jurescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Anapatmol Research Center, Victor Babe\u015f University of Medicine and Pharmacy, Timi\u015foara, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavia Cornelia","family":"Vi\u0163a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Anapatmol Research Center, Victor Babe\u015f University of Medicine and Pharmacy, Timi\u015foara, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorina Maria","family":"T\u0103ban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Anapatmol Research Center, Victor Babe\u015f University of Medicine and Pharmacy, Timi\u015foara, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Hurmuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Anapatmol Research Center, Victor Babe\u015f University of Medicine and Pharmacy, Timi\u015foara, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana Nadina","family":"Szilagyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pathology, Pius Br\u00eenzeu Emergency County Hospital, Timi\u015foara, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daciana","family":"Grujic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Plastic Surgery, Victor Babe\u015f University of Medicine and Pharmacy, Timi\u015foara, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin Tudor","family":"Popa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Anapatmol Research Center, Victor Babe\u015f University of Medicine and Pharmacy, Timi\u015foara, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorin","family":"Dema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Oncology, Victor Babe\u015f University of Medicine and Pharmacy, Timi\u015foara, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"26736","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"\"[1] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin, 2023, 73(1):17-48. https:\/\/doi.org\/10.3322\/caac.21763","DOI":"10.3322\/caac.21763"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"[2] Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, Bray F. Cancer statistics for the year 2020: an overview. Int J Cancer, 2021, 149(4):778-789. https:\/\/doi.org\/10.1002\/ijc.33588","DOI":"10.1002\/ijc.33588"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"[3] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3):209-249. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"[4] Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol, 2001, 19(16):3622-3634. https:\/\/doi.org\/10.1200\/JCO.2001.19.16.3622","DOI":"10.1200\/JCO.2001.19.16.3622"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"[5] Ruiter DJ, Spatz A, van den Oord JJ, Cook MG; Pathology Committee of the European Organization Research and Treatment of Cancer (EORTC) Melanoma Group. Pathologic staging of melanoma. Semin Oncol, 2002, 29(4):370-381. https:\/\/doi.org\/10.1053\/sonc.2002.34116","DOI":"10.1053\/sonc.2002.34116"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"[6] Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S. Evolving treatment options for melanoma brain metastases. Lancet Oncol, 2015, 16(13):e486-e497. https:\/\/doi.org\/10.1016\/S1470-2045(15)00141-2","DOI":"10.1016\/S1470-2045(15)00141-2"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"[7] Leong TW, McCook G, Frampton CM, Robinson BA, James ML. Adjuvant nodal field radiation in resected stage III melanoma: a single-centre retrospective study in Christchurch, New Zealand. J Med Imaging Radiat Oncol, 2022, 66(7):1003-1013. https:\/\/doi.org\/10.1111\/1754-9485.13438","DOI":"10.1111\/1754-9485.13438"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"[8] Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J, Siegel RL. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin, 2022, 72(5):409-436. https:\/\/doi.org\/10.3322\/caac.21731","DOI":"10.3322\/caac.21731"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"[9] Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M, Mandal\u00e0 M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Combined Vemurafenib and Cobimetinib in BRAF-mutated melanoma. N Engl J Med, 2014, 371(20):1867-1876. https:\/\/doi.org\/10.1056\/NEJMoa1408868","DOI":"10.1056\/NEJMoa1408868"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"[10] Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2018, 19(5):603-615. https:\/\/doi.org\/10.1016\/S1470-2045(18)30142-6","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"[11] Gogas H, Dummer R, Ascierto PA, Arance A, Mandal\u00e0 M, Liszkay G, Garbe C, Schadendorf D, Krajsov\u00e1 I, Gutzmer R, Sileni VC, Dutriaux C, Yamazaki N, Loquai C, Queirolo P, Jan de Willem G, Sellier AT, Suissa J, Murris J, Gollerkeri A, Robert C, Flaherty KT. Quality of life in patients with BRAF-mutant melanoma receiving the combination Encorafenib plus Binimetinib: results from a multicentre, open-label, randomised, phase III study (COLUMBUS). Eur J Cancer, 2021, 152:116-128. https:\/\/doi.org\/10.1016\/j.ejca.2021.04.028","DOI":"10.1016\/j.ejca.2021.04.028"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"[12] Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsov\u00e1 I, Liszkay G, Loquai C, Mandal\u00e0 M, Schadendorf D, Yamazaki N, di Pietro A, Cantey-Kiser J, Edwards M, Ascierto PA. COLUMBUS 5-year update: a randomized, open-label, phase III trial of Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in patients with BRAFV600-mutant melanoma. J Clin Oncol, 2022, 40(36):4178-4188. https:\/\/doi.org\/10.1200\/JCO.21.02659","DOI":"10.1200\/JCO.21.02659"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"[13] Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, Garbe C. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol, 2002, 147(1):62-70. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04867.x","DOI":"10.1046\/j.1365-2133.2002.04867.x"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"[14] Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol, 2004, 86(4):172-178. https:\/\/doi.org\/10.1002\/jso.20079","DOI":"10.1002\/jso.20079"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"[15] McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer, 2005, 103(5):1000-1007. https:\/\/doi.org\/10.1002\/cncr.20866","DOI":"10.1002\/cncr.20866"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"[16] Thoelke A, Willrodt S, Hauschild A, Schadendorf D. Primary extracutaneous malignant melanoma: a comprehensive review with emphasis on treatment. Onkologie, 2004, 27(5):492-499. https:\/\/doi.org\/10.1159\/000080372","DOI":"10.1159\/000080372"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"[17] Maher EA, Mietz J, Arteaga CL, DePinho RA, Mohla S. Brain metastasis: opportunities in basic and translational research. Cancer Res, 2009, 69(15):6015-6020. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4347","DOI":"10.1158\/0008-5472.CAN-08-4347"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"[18] Gugger A, Barnhill RL, Seifert B, Dehler S, Moch H, Lugassy C, Marques-Maggio E, Rushing EJ, Mihic-Probst D. Cutaneous melanoma with brain metastasis: report of 193 patients with new observations. PLoS One, 2016, 11(5):e0156115. https:\/\/doi.org\/10.1371\/journal.pone.0156115","DOI":"10.1371\/journal.pone.0156115"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"[19] Intern\u00f2 V, Sergi MC, Metta ME, Guida M, Trerotoli P, Strippoli S, Circelli S, Porta C, Tucci M. Melanoma brain metastases: a retrospective analysis of prognostic factors and efficacy of multimodal therapies. Cancers (Basel), 2023, 15(5):1542. https:\/\/doi.org\/10.3390\/cancers15051542","DOI":"10.3390\/cancers15051542"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"[20] Qian M, Ma MW, Fleming NH, Lackaye DJ, Hernando E, Osman I, Shao Y. Clinicopathological characteristics at primary melanoma diagnosis as risk factors for brain metastasis. Melanoma Res, 2013, 23(6):461-467. https:\/\/doi.org\/10.1097\/CMR.0000000000000015","DOI":"10.1097\/CMR.0000000000000015"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"[21] Schuchter LM, Green R, Fraker D. Primary and metastatic diseases in malignant melanoma of the gastrointestinal tract. Curr Opin Oncol, 2000, 12(2):181-185. https:\/\/doi.org\/10.1097\/00001622-200003000-00014","DOI":"10.1097\/00001622-200003000-00014"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"[22] Liang KV, Sanderson SO, Nowakowski GS, Arora AS. Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc, 2006, 81(4):511-516. https:\/\/doi.org\/10.4065\/81.4.511","DOI":"10.4065\/81.4.511"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"[23] Goodman PL, Karakousis CP. Symptomatic gastrointestinal metastases from malignant melanoma. Cancer, 1981, 48(4):1058-1059. https:\/\/doi.org\/10.1002\/1097-0142(19810815)48:4<1058::aid-cncr2820480434>3.0.co;2-z","DOI":"10.1002\/1097-0142(19810815)48:4<1058::AID-CNCR2820480434>3.0.CO;2-Z"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"[24] Goral V, Ucmak F, Yildirim S, Barutcu S, Ileri S, Aslan I, Buyukbayram H. Malignant melanoma of the stomach presenting in a woman: a case report. J Med Case Rep, 2011, 5:94. https:\/\/doi.org\/10.1186\/1752-1947-5-94","DOI":"10.1186\/1752-1947-5-94"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"[25] Blecker D, Abraham S, Furth EE, Kochman ML. Melanoma in the gastrointestinal tract. Am J Gastroenterol, 1999, 94(12):3427-3433. https:\/\/doi.org\/10.1111\/j.1572-0241.1999.01604.x","DOI":"10.1111\/j.1572-0241.1999.01604.x"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"[26] O'Connell JB, Whittemore DM, Russell JC, Ellis WA, Becker DR. Malignant melanoma metastatic to the cystic and common bile ducts. Cancer, 1984, 53(1):184-186. https:\/\/doi.org\/10.1002\/1097-0142(19840101)53:1<184::aid-cncr2820530132>3.0.co;2-z","DOI":"10.1002\/1097-0142(19840101)53:1<184::AID-CNCR2820530132>3.0.CO;2-Z"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"[27] Flanagan M, Solon J, Chang KH, Deady S, Moran B, Cahill R, Shields C, Mulsow J. Peritoneal metastases from extra-abdominal cancer - a population-based study. Eur J Surg Oncol, 2018, 44(11):1811-1817. https:\/\/doi.org\/10.1016\/j.ejso.2018.07.049","DOI":"10.1016\/j.ejso.2018.07.049"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"[28] Mittendorf EA, Lim SJ, Schacherer CW, Lucci A, Cormier JN, Mansfield PF, Gershenwald JE, Ross MI, Lee JE. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg, 2008, 195(3):363-368. https:\/\/doi.org\/10.1016\/j.amjsurg.2007.12.018","DOI":"10.1016\/j.amjsurg.2007.12.018"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"[29] Giovagnoni A, Giorgi C, Goteri G. Tumours of the spleen. Cancer Imaging, 2005, 5(1):73-77. https:\/\/doi.org\/10.1102\/1470-7330.2005.0002","DOI":"10.1102\/1470-7330.2005.0002"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"[30] Gatenby PAC, Mudan SS, Wotherspoon AC. Splenectomy for non-haematological metastatic malignant disease. Langenbecks Arch Surg, 2011, 396(5):625-638. https:\/\/doi.org\/10.1007\/s00423-011-0746-2","DOI":"10.1007\/s00423-011-0746-2"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"[31] Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F. Bone metastases: an overview. Oncol Rev, 2017, 11(1):321. https:\/\/doi.org\/10.4081\/oncol.2017.321","DOI":"10.4081\/oncol.2017.321"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"[32] Younes RN, Abrao F, Gross J. Pulmonary metastasectomy for colorectal cancer: long-term survival and prognostic factors. Int J Surg, 2013, 11(3):244-248. https:\/\/doi.org\/10.1016\/j.ijsu.2013.01.003","DOI":"10.1016\/j.ijsu.2013.01.003"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"[33] Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology, 2011, 118(9):1881-1885. https:\/\/doi.org\/10.1016\/j.ophtha.2011.01.040","DOI":"10.1016\/j.ophtha.2011.01.040"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"[34] Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM, Paci E; EUROCARE Working Group. Incidence of uveal melanoma in Europe. Ophthalmology, 2007, 114(12):2309-2315. https:\/\/doi.org\/10.1016\/j.ophtha.2007.01.032","DOI":"10.1016\/j.ophtha.2007.01.032"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"[35] Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer, 1998, 83(8):1664-1678. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"[36] Micu E, Juzeniene A, Moan J. Comparison of the time and latitude trends of melanoma incidence in anorectal region and perianal skin with those of cutaneous malignant melanoma in Norway. J Eur Acad Dermatol Venereol, 2011, 25(12):1444-1449. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04023.x","DOI":"10.1111\/j.1468-3083.2011.04023.x"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"[37] Cagir B, Whiteford MH, Topham A, Rakinic J, Fry RD. Changing epidemiology of anorectal melanoma. Dis Colon Rectum, 1999, 42(9):1203-1208. https:\/\/doi.org\/10.1007\/BF02238576","DOI":"10.1007\/BF02238576"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"[38] Chen H, Cai Y, Liu Y, He J, Hu Y, Xiao Q, Hu W, Ding K. Incidence, surgical treatment, and prognosis of anorectal melanoma from 1973 to 2011: a population-based SEER analysis. Medicine (Baltimore), 2016, 95(7):e2770. https:\/\/doi.org\/10.1097\/MD.0000000000002770","DOI":"10.1097\/MD.0000000000002770"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"[39] Khan M, Bucher N, Elhassan A, Barbaryan A, Ali AM, Hussain N, Mirrakhimov AE. Primary anorectal melanoma. Case Rep Oncol, 2014, 7(1):164-170. https:\/\/doi.org\/10.1159\/000360814","DOI":"10.1159\/000360814"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"[40] Zhang S, Gao F, Wan D. Effect of misdiagnosis on the prognosis of anorectal malignant melanoma. J Cancer Res Clin Oncol, 2010, 136(9):1401-1405. https:\/\/doi.org\/10.1007\/s00432-010-0793-z","DOI":"10.1007\/s00432-010-0793-z"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"[41] Row D, Weiser MR. Anorectal melanoma. Clin Colon Rectal Surg, 2009, 22(2):120-126. https:\/\/doi.org\/10.1055\/s-0029-1223844","DOI":"10.1055\/s-0029-1223844"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"[42] Stefanou A, Nalamati SPM. Anorectal melanoma. Clin Colon Rectal Surg, 2011, 24(3):171-176. https:\/\/doi.org\/10.1055\/s-0031-1286001","DOI":"10.1055\/s-0031-1286001"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"[43] S\u00e1nchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA. Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol, 2005, 173(6):1958-1965. https:\/\/doi.org\/10.1097\/01.ju.0000159207.91737.53","DOI":"10.1097\/01.ju.0000159207.91737.53"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"[44] Ramos Hernandez AM, Villareal Trujillo N. Melanoma primario de pene [Primary penile melanoma]. Urol Colomb, 2016, 25(1):37-40. https:\/\/doi.org\/10.1016\/j.uroco.2015.12.006\"","DOI":"10.1016\/j.uroco.2015.12.006"}],"container-title":["Romanian Journal of Morphology and Embryology"],"original-title":[],"link":[{"URL":"https:\/\/rjme.ro\/RJME\/resources\/files\/660325479488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:46:12Z","timestamp":1768819572000},"score":1,"resource":{"primary":{"URL":"https:\/\/rjme.ro\/archive\/66\/3\/5\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,12]]},"published-print":{"date-parts":[[2025,12,12]]}},"URL":"https:\/\/doi.org\/10.47162\/rjme.66.3.05","relation":{},"ISSN":["1220-0522","2066-8279"],"issn-type":[{"value":"1220-0522","type":"print"},{"value":"2066-8279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}